Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001217263 | SCV001389097 | uncertain significance | Hereditary spastic paraplegia 47 | 2019-04-30 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine with proline at codon 83 of the AP4B1 protein (p.Ala83Pro). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and proline. This variant is present in population databases (rs149478319, ExAC 0.006%). This variant has not been reported in the literature in individuals with AP4B1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome Diagnostics Laboratory, |
RCV001847194 | SCV002105532 | uncertain significance | Hereditary spastic paraplegia | 2019-06-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002562425 | SCV003706272 | uncertain significance | Inborn genetic diseases | 2022-05-13 | criteria provided, single submitter | clinical testing | The c.247G>C (p.A83P) alteration is located in exon 3 (coding exon 2) of the AP4B1 gene. This alteration results from a G to C substitution at nucleotide position 247, causing the alanine (A) at amino acid position 83 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV001217263 | SCV004050699 | uncertain significance | Hereditary spastic paraplegia 47 | 2023-04-11 | criteria provided, single submitter | clinical testing |